Skip to main content
PRLD $3.23 -0.77%
PRLD logo
PRLD · Prelude Therapeutics Inc
Track PRLD — free
$3.23 -0.03 (-0.77%) At close · Nov 20 Play latest call Q3 2025 earnings call transcript
Market Cap
$258.63M
Shares
80.07M
Volume · Nov 20 300.1K Avg daily vol (3M) 434.45K
All webcasts

Earnings call · FY2026 Q3

Prelude Therapeutics Inc (PRLD) Q3 2026 Earnings Call

Concluded Nov 16, 2026
Nov 16, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $5.65M -13.1% YoY
Diluted EPS -$0.12
Net income -$12.54M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 16, 2026
Prelude Therapeutics began Phase 1 enrollment for PRT13722 in HR+/HER2- breast cancer, expects proof-of-concept data in the 2nd half of 2027, and expects cash to fund operations into the second quarter of 2028.
10-Q report · filed Nov 16, 2026
Prelude began Phase 1 enrollment for PRT13722 after September 2026 FDA clearance and entered an October 2026 clinical trial collaboration with Eli Lilly and Company to evaluate abemaciclib and imlunestrant combinations in HR+/HER2- breast cancer.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Full-screen source Call document